Clinical trial · Observational
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Thrombosis in Diffuse Large B-cell Lymphoma: Impact on Outcome, Evaluation, and Comparison of Predictive Models of Thrombotic Risk: Multicentre Retrospective Observational Study. The PREDIC-TO (PREDICt ThrOmbosis) Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large B-cell Lymphoma (DLBCL) Primary Endpoints: Measure thrombotic risk factors in existing models Determine occurrence, type, and timing of venous thrombotic events Secondary Endpoints: Assess performance of models in patients without thrombotic events at diagnosis Evaluate dynamic risk factors during DLBCL treatment Identify additional risk factors not included in published models Analyze overall survival and VTE-free survival Methodology: Real-world cohort study of DLBCL patients Collection of static and dynamic risk factors Correlation analysis of risk factors with thrombotic events Development and validation of DLBCL-specific predictive model Conclusion: This study aims to compare existing predictive models and develop a DLBCL-specific model to aid in identifying high-risk patients and inform thromboprophylaxis decisions. Results will contribute to improved understanding and management of thrombotic risk in DLBCL.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Measurement of thrombotic events
- timeFrame
- From the date of diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) to the occurrence of a thrombotic event (arterial or venous), death, loss to follow-up, or a maximum period of 24 months from diagnosis, whichever comes first.
- description
- Measurement of thrombotic risk factors present in the Khorana, Throly and Model IX scores. Thrombotic events after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects aged ≥ 18 years * Histological diagnosis of DLBCL * Informed consent freely given and obtained Exclusion Criteria: * Active anticoagulant therapy at the time of diagnosis * Start of prophylactic heparin following diagnosis * Absence of necessary data to extrapolate risk scores (Khorana, Throly and Model IX) at diagnosis
References
Publications (0)
Data not yet available